Last 27 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.79 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 15.31 | — | — | 14.56 | 103.16 | 20.08 | 16.02 | 37.39 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -61.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.80 | 2.25 | 1.10 | 1.46 | 4.54 | 1.02 | 1.18 | 2.12 | 1.73 | 1.54 | 4.77 | 2.26 | 1.89 | 1.30 | 1.51 | — | 5.71 | 0.55 | 0.65 | 1.36 | 1.65 |
| — | +120.8% | -6.7% | -30.9% | +162.4% | -33.7% | -75.3% | -6.4% | -8.3% | +18.0% | +216.1% | — | -66.9% | +137.9% | +130.3% | — | +245.3% | -73.3% | -64.1% | -78.1% | -48.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 33.0% | — | — | 49.8% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -50.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1366.4% | — | — | -1229.3% | -1764.9% | -1863.2% | -981.2% | -1014.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -21.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -1834.5% | — | — | -3873.2% | -1657.0% | -1765.1% | -917.1% | -933.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | -314.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -110.7% | -17.0% | -22.9% | -66.5% | -16.9% | -20.3% | -15.6% | -12.5% | -11.1% | -12.5% | -12.2% | -22.5% | -28.5% | -21.4% | -21.5% | — | -22.0% | -12.5% | -19.2% | -15.5% | -16.1% |
| — | +16.3% | -46.8% | -433.5% | -51.7% | -62.4% | -28.3% | +44.6% | +60.9% | +41.6% | +43.4% | — | -29.4% | -71.0% | -12.0% | — | -36.8% | -21.7% | -74.4% | -196.4% | -443.4% | |
| ROA | -69.0% | -10.9% | -13.2% | -36.4% | -10.6% | -13.5% | -10.9% | -9.0% | -8.5% | -9.8% | -9.3% | -16.0% | -18.0% | -16.9% | -22.6% | -16.6% | -13.7% | -8.3% | -13.4% | -11.1% | -11.9% |
| — | +19.1% | -21.0% | -303.2% | -24.0% | -38.1% | -17.1% | +43.7% | +52.8% | +42.1% | +58.7% | +3.2% | -31.7% | -103.2% | -68.9% | -49.2% | -14.9% | -8.4% | -65.9% | -170.6% | -389.6% | |
| ROIC | -58.8% | -13.6% | -17.6% | -12.4% | -11.8% | -16.6% | -13.9% | -11.2% | -11.5% | -18.7% | -37.7% | -51.6% | -33.9% | -48.4% | -64.1% | -24.1% | -16.8% | -9.6% | -17.0% | -18.0% | -23.7% |
| — | +17.8% | -26.6% | -10.7% | -2.5% | +11.2% | +63.0% | +78.2% | +66.0% | +61.4% | +41.2% | -114.5% | -101.1% | -405.0% | -276.2% | -33.6% | +28.8% | +51.8% | +59.1% | +57.6% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.85 | 0.41 | 0.36 | 0.85 | 0.45 | 0.39 | 0.33 | 0.28 | 0.23 | 0.19 | 0.24 | 0.20 | 0.56 | 0.39 | 0.03 | — | 0.54 | 0.47 | 0.40 | 0.35 | 0.31 |
| — | +5.5% | +10.2% | +202.9% | +93.9% | +99.7% | +37.0% | +42.8% | -58.2% | -50.5% | +787.7% | — | +3.2% | -15.8% | -93.3% | — | +72.6% | +66.9% | +53.1% | +45.9% | +2684.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.90 | 9.55 | 8.13 | 6.90 | 6.71 | 5.98 | 9.41 | 8.79 | 11.23 | 13.28 | 13.18 | 8.87 | 5.15 | 7.65 | 9.15 | 6.56 | 5.05 | 6.77 | 9.85 | 11.79 | 14.30 |
| — | +59.8% | -13.7% | -21.5% | -40.2% | -55.0% | -28.6% | -0.8% | +117.9% | +73.5% | +44.1% | +35.1% | +2.0% | +13.1% | -7.2% | -44.4% | -64.7% | -64.5% | -6.8% | +39.5% | +107.0% | |
| Quick Ratio | 6.90 | 9.55 | 8.13 | 6.90 | 6.71 | 5.98 | 9.41 | 8.79 | 11.23 | 13.28 | 13.18 | 8.87 | 5.15 | 7.65 | 9.15 | 6.56 | 5.05 | 6.77 | 9.85 | 11.79 | 14.30 |
| — | +59.8% | -13.7% | -21.5% | -40.2% | -55.0% | -28.6% | -0.8% | +117.9% | +73.5% | +44.1% | +35.1% | +2.0% | +13.1% | -7.2% | -44.4% | -64.7% | -64.5% | -6.8% | +39.5% | +107.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -69.03 | -54.63 | -73.41 | — | — | -117.12 | -137.20 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KRRO stock.
Korro Bio, Inc.'s current P/E is -0.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Korro Bio, Inc.'s current operating margin is -1366.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Korro Bio, Inc.'s business trajectory between earnings reports.